Here's a press release from the company: http://asteriasbiotherapeutics.com/asterias-biotherapeutics-... They're doing a dosing study, with escalating number of cells injected. Results are promising, but the study includes no controls, so there is no way to know if the cell-based treatment is better than no treatment.

The current study is open-label (i.e. not blinded) single-arm (no controls). Once they establish the right dose, they will need to do a double-blind randomized controlled study to find out if it works.